Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.
about
Recent progress in West Nile virus diagnosis and vaccinationA new DNA vaccine fused with the C3d-p28 induces a Th2 immune response against amyloid-betaSynthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine.A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodiesTLR3- and MyD88-dependent signaling differentially influences the development of West Nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidateA mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses.DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice.West Nile virus: the complex biology of an emerging pathogen.The human antibody response to dengue virus infectionTechnologies for the development of West Nile virus vaccines.Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases.Plasticity of a critical antigenic determinant in the West Nile virus NY99 envelope protein domain III.An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.
P2860
Q21284433-E77536A6-63BE-432C-8D75-FE49AB91D8A5Q34094661-9628E854-3916-4E9B-84F7-E00167D881C1Q36029040-EEBD66F4-0E85-4EF0-9C44-C89E5BA3CA65Q36889041-21E9D2AF-A94F-4E44-A47C-E3F4EC2E9614Q37254256-161C5B89-41F8-4DC8-9E5D-2EA795CD9748Q37507215-3D155509-31A3-4042-BBDF-300ADDBCAD26Q37694852-1B086520-275E-4C06-9AC6-2A93BEDE69BBQ37721304-586B25F7-C2E9-433F-8464-CDC34B5B02E1Q37876095-3034A9A0-A3E2-4F49-AAC2-DBCF3E68DC67Q37987124-A70C5AB6-9C35-4928-9C28-CFA84E181E45Q38269151-60C22FFF-85F3-484F-91C9-11FCD6359690Q38342834-08FF0CB7-E660-4D94-AAE1-54F341CAD046Q38765315-C6412269-F207-4370-8BE3-3CE5B717E05FQ38866173-0E2B699B-26AD-492D-A101-6BC630D93DF8
P2860
Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Enhancement of anti-DIII antib ...... d augments protection in mice.
@ast
Enhancement of anti-DIII antib ...... d augments protection in mice.
@en
type
label
Enhancement of anti-DIII antib ...... d augments protection in mice.
@ast
Enhancement of anti-DIII antib ...... d augments protection in mice.
@en
prefLabel
Enhancement of anti-DIII antib ...... d augments protection in mice.
@ast
Enhancement of anti-DIII antib ...... d augments protection in mice.
@en
P2093
P2860
P356
P1433
P1476
Enhancement of anti-DIII antib ...... d augments protection in mice.
@en
P2093
Donald M Carter
Erin Mehlhop
Matthew D Dunn
Matthew R Vogt
Ted M Ross
P2860
P2888
P356
10.1186/1743-422X-7-95
P577
2010-05-12T00:00:00Z
P6179
1053622404